Resource Library

Whitepapers

Overcoming cell line development challenges through early-stage assessment and management

WHITEPAPER - Overcoming cell line development challenges through early-stage assessment and management

Cell line development (CLD) timelines, product quality, and drug stability continue to impose difficult bottlenecks that disrupt clinical trials, bringing attention to CLD practices and opportunities to achieve faster timelines. In this whitepaper, we discuss how to overcome the challenges in cell line development through early-stage assessment and management. We also share how Samsung Biologics balances quality and titer through the application of high-throughput analytic methods to cut risk, time, and cost. 

WHITEPAPER - Overcoming cell line development challenges through early-stage assessment and management

Cell line development (CLD) timelines, product quality, and drug stability continue to impose difficult bottlenecks that disrupt clinical trials, bringing attention to CLD practices and opportunities to achieve faster timelines. In this whitepaper, we discuss how to overcome the challenges in cell line development through early-stage assessment and management. We also share how Samsung Biologics balances quality and titer through the application of high-throughput analytic methods to cut risk, time, and cost. 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION